Fabry disease: Effective tissue substrate depletion following enzyme replacement in α-galactosidase A deficient mice. • 607
Yiannis A. Ioannou(Icahn School of Medicine at Mount Sinai), Robert J. Desnick(Icahn School of Medicine at Mount Sinai), Kenneth M. Zeidner(Icahn School of Medicine at Mount Sinai), Beth Ann Friedman(Icahn School of Medicine at Mount Sinai)
Cited by 0
Related Papers
Agalsidase-Beta Therapy for Advanced Fabry Disease
|Annals of Internal Medicine|2007|565
Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick disease
|Nature Genetics|1995|477
Functional variants in the <i>LRRK2</i> gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease
|Science Translational Medicine|2018|410
Hepatic Niemann-Pick C1–like 1 regulates biliary cholesterol concentration and is a target of ezetimibe
|Journal of Clinical Investigation|2007|372